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Background: Tryptophan metabolism via the kynurenine pathway is considered the link between the immune and endocrine systems. 
Dysregulation of serotonergic transmission can stem from the direct influence of interferon-a on the activity of serotonergic receptors 
5-HT1A and 5-HT2A, and from its indirect effect on tryptophan metabolism. Induction of the kynurenine pathway increases the concentration 
of neurotoxic kynurenine metabolites, and the activity of kynurenine derivatives is linked to the onset of depression. The aim of our study 
was to evaluate the relationships between depressive symptoms and kynurenine, tryptophan, anthranilic acid and kynurenic acid concen­
trations, indolamine 2,3-dioxygenase (IDO) activity and tryptophan availability to the brain. Methods: The study followed a prospective 
longitudinal cohort design. We evaluated 101 patients with chronic hepatitis C who were treated with pegylated interferon-a2a, and 
40 controls who were awaiting treatment. We evaluated the relationships between total score on the Montgomery-Äsberg Depression 
Rating Scale and kynurenine, tryptophan, anthranilic acid and kynurenic acid concentrations, IDO activity and tryptophan availability to the 
brain. A logistic regression model was adapted for the diagnosis of major depressive disorder at each time point, taking into account 
changes in parameters of the kynurenine pathway between a given time point and the baseline measurement. Results: Of the treated 
patients, 44% fulfilled the criteria for major depressive disorder at least once during the 24 weeks of treatment. Anthranilic acid concentra­
tions were significantly increased compared to baseline for all time points except week 2. Tryptophan availability showed a significant de­
crease (ß = -0.09, p  = 0.01) only in week 12 of treatment. Over time, kynurenine, tryptophan and anthranilic acid concentrations, as well 
as IDO activity and tryptophan availability to the brain, were significantly associated with total score on the Montgomery-Äsberg Depres­
sion Rating Scale. A logistic regression model revealed that participants with decreased tryptophan availability to the brain at 12 weeks of 
treatment and participants with increased anthranilic acid concentrations at week 24 of treatment were at increased risk for diagnosis of 
major depressive disorder (odds ratios 2.92 and 3.59, respectively). Limitations: This study had an open-label design in a population 
receiving naturalistic treatment. Conclusion: The present study provides the first direct evidence of the role of anthranilic acid in the 
pathogenesis of inflammation-induced major depressive disorder during treatment for hepatitis C with pegylated interferon-a2a.
Introduction
Tryptophan is an essential am ino acid  that m ust be supplied 
from  external sources. Four b iosynthetic pathw ays orig in ­
ate  fro m  try p to p h an : sy n th es is  o f p ro te in s , sy n th es is  of 
serotonin, synthesis of tryptam ine and the kynurenine path­
w ay (Fig. 1). T ry p top h an  m etab olism  via the ky nu renine 
path w ay  is con sid ered  the lin k  betw een  the im m u ne and 
endocrine system s. Lapin and O xenkrug1 proposed a m ech­
an ism  o f try p to p h an  d ep letio n  as a resu lt o f ky nu ren ine
pathw ay activation, leading to depression. D uring treatm ent 
w ith  in te rfe ro n , a d ecrea se  in  sero to n in  lev e ls  h a s  b een  
observed  in b oth  p lasm a2 and in b lood  p latelets,3 and this 
d ecrease  h as b een  co rre la ted  w ith  in ten sified  d ep ressiv e  
sym ptom s. D ysregulation o f serotonergic transm ission can 
stem  from  the direct interference o f in terferon-a in the activ­
ity of serotonergic receptors 5-H T1A and 5-H T2A, and from  its 
indirect effects on tryptophan m etabolism .4,5
T h e in d u c tio n  o f th e  k y n u re n in e  p a th w a y  in c re a se s  
the co n ce n tra tio n  o f n e u ro to x ic  k y n u ren in e  m e ta b o lites
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Role of anthranilic acid in increase of depressive sym ptom s
Fig. 1: Diagram of tryptophan metabolism.
3-h y d ro x y k y n u ren in e  and  q u in o lin ic  ac id , w h ich  h av e  a 
toxic  in flu en ce  on the cen tra l n erv o u s system . The a c tiv ­
ity  o f th ese  k y n u ren in e  d eriv a tiv es  is lin k ed  to the onset 
o f d e p re ss io n .6 Q u in o lin ic  ac id  is  a s tro n g  N -m ethyl-D - 
a sp a rta te  re c e p to r  a g o n is t  th a t c a u ses  e x c ito to x ic ity  in  
the n eu ro n s. The im b alan ce  b e tw een  q u in o lin ic  acid  and  
k y n u re n ic  a c id  (an  N -m e th y l-D -a s p a r ta te  a n ta g o n is t)  
m igh t d isturb  glu tam ate neu rotransm ission7,8 —  called  the 
"n e u ro d e g e n e ra tio n  h y p o th e s is ."9
"Sickness behaviour" is a term  that describes behavioural 
(reduced food intake, sleep disturbances, decreased novelty- 
seek in g), em o tio n al (anhed onia) and  cog n itiv e  (im p aired  
attention) changes ind uced  by  inflam m ation .10 S im ilarities 
betw een the sym ptom s of sickness behaviour and depression 
alerted scholars to the role of inflam m ation in the pathogen­
esis o f d ep re ss io n .11-13 The e ffect o f in flam m atio n  on the 
in d u ctio n  o f d ep ressive sym p tom s h as b een  inv estigated  
using d ifferent stim uli to ind uce perip heral in flam m atory 
activity. Prospective experim ental studies have relied on 1 of 
3 paradigm s to induce inflam m ation: vaccination, endotoxin 
injection and interferon treatm ent.14
R esearch  find ings hav e in d icated  p o ten tia l p athom ech- 
anism s by  w hich  inflam m ation is connected to depression: 
altered neuroplasticity  (as an effect o f decreased  expression 
of brain-derived  neuroprotective horm one15), altered dopa­
m inergic system ,16 sustained activation of the hy p othalam ic- 
pituitary-adrenal axis,17 altered serotonin system 18 and altered 
glutam ate neu rotransm ission .19
Immunotherapy w ith interferon-a facilitates an opportunity 
for the prospective observation of the occurrence of depressive 
symptoms. It induces depression in 20% to 70% of patients.20 So 
far, investigations into interferon-a treatment have confirm ed a 
decrease in plasm a tryptophan, but not in tryptophan availabil­
ity to the brain (the ratio of tryptophan to com peting amino 
acids).2,6,21,22 Decreased tryptophan availability to the brain has 
been detected in only 1 study, by Capuron and colleagues.23
The aim  o f o u r stu d y w as to ev alu ate  the re latio n sh ip  
betw een kynurenine, tryptophan, kynurenic acid and anthra- 
nilic acid concentrations, indolam ine 2,3-dioxygenase (ID O) 
activ ity , try p to p h an  av a ila b ility  to the b ra in  and dep res­
sive sym ptom s. W e also evaluated the effect of tryptophan 
catabolites on the diagnosis of depression.
M ethods
Sample
O ur sam p le in clu d ed  141 ad u lts w ith  chronic  h ep atitis  C 
infection (detectable plasm a H C V  RN A  levels on the Cobas 
A m plicor H C V  M onitor Test version 2.0; Roche Diagnostics)
Indolamine 2,3-dioxygenase 1 and 2
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Tryptophan 2,3-dioxygenase
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and com pensated liver disease, w ho qualified for treatm ent 
w ith pegylated interferon-a2a (PEG -IFN -a2a). Patients w ere 
at least 18 years old and had  previously untreated hepatitis 
C. A ll patients w ere recruited from  the sam e geographic area 
and belonged to native Polish populations.
A part from  chronic hepatitis C, patients had  no other clin­
ical conditions that m ight have influenced their im m une sta­
tus (e.g., acute or chronic infections, pregnancy, autoim m une 
and neoplastic diseases), nor w ere they receiving any im m u­
nosupp ressive treatm ent. Patients w ho w ere actively using 
alcohol or taking drugs w ere excluded from  the study. O ther 
e x c lu s io n  c r ite r ia  in c lu d e d  p re v io u s  tre a tm e n t  w ith  
interferon-a, a history of traum atic brain injury or neurologic 
or psychiatric disorders at baseline (m ajor depressive disor­
der [M D D ], b ip o lar d isord er, sch izop hrenia). N one o f the 
participants w as receiving antidepressants or anxiety m edi­
cations 6  m onths before inclusion in the study.
The participants in the current study w ere also a subsam ­
ple of participants from  previous studies analyzing the effect 
of interferon treatm ent on the activation of peripheral blood 
m ononuclear cells (n =  24), the outcom es of antiviral treat­
m ent (n =  22) and alterations in the m etabolism  o f trypto­
p han after interferon treatm ent (n =  76 and n =  24).24-26
Inform ed consent w as obtained  from  each p atient in the 
study, and the stud y p rotoco l fo llow ed  the eth ical gu id e­
lin es o f the  1975 H els in k i D e clara tio n . F u rth erm o re , the 
study w as approved  by  the ethical com m ittee at W roclaw  
M edical U niversity.
Study design
The study follow ed a prospective longitudinal cohort design. 
W e exam ined neurobiological and behavioural variables in 
stud y p artic ip an ts receiv ing  treatm en t w ith  P E G -IF N -a2a  
and  rib av ir in  (trea tm en t g rou p , n =  101) and  in a group 
aw aiting treatm ent (controls, n =  40). W e conducted a cross­
sectional assessm ent of tryptophan and its m etabolites in the 
peripheral blood of the treatm ent group at baseline and w eek 
24 to com pare them  w ith findings for the control group.
Participants in the treatm ent group w ere evaluated 6 times: 
before they started treatm ent (w eek 0) and at w eeks 2, 4, 8, 12 
and 24. T hey received  P E G -IF N -a2a  (P egasys; H offm ann- 
LaRoche) 180 pg once per w eek. They also received ribavirin 
(S ch er in g -P lo u g h  C o rp .) 1000 m g p e r d ay  if  th e ir  b o d y  
w eight w as less than 75 kg, or 1200 m g per day if their body 
w eight w as 75 kg or m ore. The duration of treatm ent w as 
48 w eeks, except for p atients w ith  genotype 3 hepatitis C, 
w ho w ere treated for 24 weeks.
P artic ip ants aw aitin g  treatm en t w ith  P E G -IF N -a2a  and 
ribavirin (controls) w ere exam ined twice: at the beginning of 
the study and 24 w eeks later.
Psychiatric evaluation
P artic ip an ts  u n d erw en t a b aselin e  p sy ch ia tric  ev alu atio n  
using the Present State Exam ination from  the Schedules of 
C linical A ssessm ent in N europ sychiatry  (SC A N  2 .0)27 p er­
form ed by  a senior board-certified  investigator. Categorical
d e p re ss iv e  e p iso d e s  d u rin g  tre a tm e n t w e re  d ia g n o se d  
accord ing to the D SM -IV  criteria for A xis I d isorders. W e 
u sed  th e  M o n tg o m e ry -Ä sb e rg  D ep re ssio n  R a tin g  Scale  
(M AD RS) to assess the severity of depressive sym ptom s.28
Laboratory assessments
A t ea ch  a ssessm en t p o in t b lo o d  sam p les w ere  co llected  
b etw een 0800 h  and 0900 h  after overnight fasting. W e per­
form ed  q u an tita tiv e  d eterm in atio n  o f p lasm a free am ino 
acid s using the P ico-T ag m ethod  (W aters). A s an in ternal 
standard, w e used m ethionine sulfoxide at a concentration of 
0.8 m M  in 0.1 M  H Cl (Sigma-Aldrich). The follow ing analytical 
stages w ere perform ed: sam ples w ere dep rotein ized  using 
ultrafiltration (M icrocon filter, M illipore); sam ples w ere de- 
r iv atized  using  p h en y liso tio cy an ate ; sam p les w ere d eter­
m ined  using  U V -v isib le  h igh -p erform an ce liqu id  chrom a­
to g ra p h y ; in d iv id u a l am in o  a c id s  w e re  id e n tifie d ; and  
concentrations w ere calculated. Sam ple separation w as per­
form ed in reverse-phase m ode on the C18 Pico-Tag chrom a­
tography colum n, and absorbance of analytes w as m easured 
at 254 nm . W e used the Em pow er program  (W aters) to collect 
and com pile data. W e determ ined the follow ing am ino acids: 
tyrosine, valine, isoleucine, leucine and phenylalanine. These 
am ino acids com pete w ith  tryptophan for transport across 
the b lood -brain  barrier, so they are referred to as com peting 
am ino acids (CA A s). W e calculated the plasm a CA A  value 
b y  su m m in g  the tyrosin e , v a lin e , iso leu cin e, leu cin e  and 
phenylalanine concentrations.
The m eth od  for am ino acid s an alysis  used  in the p res­
en t s tu d y  is c o n tro lle d  b y  th e E u ro p e a n  R e sea rch  N e t­
w o rk  fo r In h e rite d  D iso rd ers  o f M eta b o lism  (E R N D IM , 
M C A  L aboratory).
W e m easu red  k y n u ren in e  co n cen tra tio n s  a cco rd in g  to 
H olm es.29 U sing a variable w avelength detector, the colum n 
effluent w as m onitored  at 365 nm . The m obile p hase con­
sisted  o f 0.1 M  acetic acid  and  0.1 M  am m oniu m  acetate 
(pH 4.65) containing 2%  acetonitrile, and it w as pum ped at a 
flow  rate o f 0.2 m L /m in .
W e determ ined tryptophan, anthranilic acid and kynurenic 
acid concentrations using high-perform ance liquid chrom a­
tography according to the m ethod of Herve and colleagues.30 
The chrom atographic equipm ent w as an A gilent 1200 series 
liquid chrom atography system  (A gilent Technologies), com ­
posed of a G 1322A  degasser, a G 1311A  quaternary pum p, a 
G 1329A  autosam pler and a G 1330B therm ostat for the auto­
sa m p ler, a H P 1050  v a r ia b le  w a v e le n g th  d ete c to r  an d  a 
H P1046A  fluorescence d etector. D etectors w ere connected  
w ith a Spherisorb 3 pm  O D S2 150 x 2.1 m m  colum n (W aters).
C olum n efflu ent w as m on itored  using  a program m able  
flu o rescen ce  d etecto r. O p tim ized  co n d itio n s  w ere  d ete r­
m ined  by  recording fluorescence spectra w ith  a stop-flow  
technique. Excitation and em ission w avelengths w ere set at 
2 5 4 / 4 0 4  n m  fo r  try p to p h a n  a n d  k y n u re n ic  a c id , and  
3 2 0 /4 2 0  nm  for anthranilic acid. The m obile p hase consisted  
of 50 mM  acetic acid  and 0.25 M  zinc acetate (pH  4.9) con­
taining 1.2%  acetonitrile, and it w as pum ped  at a flow  rate 
of 0.2 m L /m in .
Statistical analysis
W e fitted  m u ltip le  rep eated -m easu res  reg ressio n  m od els 
u sin g  th e g e n era liz e d  estim a tin g  e q u a tio n s  p o p u la tio n - 
av eraged  m od el. In  the gen era lized  estim atin g  equ ations 
m o d els , w e u sed  an  e x ch a n g ea b le  co v a ria n ce  s tru ctu re . 
T he e ffe c t o f e x p la n a to ry  v a r ia b le s  on  d ep en d e n t v a r i­
ables w as exp ressed  u sin g  reg ressio n  coefficien ts (ß) and 
95%  con fid ence in terv als  (C Is). A nalyses w ere p erform ed  
on the treatm en t group  only. W e used  7 sep arate  m od els 
—  to ta l M A D R S score ; k y nu ren ine, try p to p h an , ky nu renic 
a c id  a n d  a n th ra n ilic  a c id  c o n c e n tr a tio n s ; k y n u re n in e : 
try p to p h a n  ra tio ; an d  try p to p h a n :C A A  ra tio  —  an d  w e 
used  tim e as an exp lan ato ry  v ariab le . T hen , to ta l M A D R S 
s c o re  w a s  re g r e s s e d  u s in g  k y n u r e n in e , t ry p to p h a n , 
a n th r a n ilic  a c id  a n d  k y n u re n ic  a c id  c o n c e n tr a t io n s , 
try p to p h a n :C A A  ra tio  an d  k y n u re n in e :try p to p h a n  ratio  
as cov ariates  to exam in e their re la tio n sh ip s w ith  d ep res­
sive sym p tom s.
W e adapted a logistic regression m odel for the d iagnosis 
of M D D  at each tim e point, taking into account changes in 
the param eters o f the kynurenine p athw ay betw een a given 
p o in t and  the b aselin e  m easu rem en t. P aram eter changes 
w ere ca teg o rized  ag a in st the  m ed ian . W e u sed  step w ise 
elim ination of statistically  nonsignificant param eters, using 
p =  0.1 as a le v e l to  re m a in  in  the m o d el. T h e e ffe c t of 
changes in b iochem ical param eters of the kynurenine p ath­
w ay on the d iag n osis o f d ep ression  w as exp ressed  using 
odds ratios (ORs) and 95%  CIs.
W e estim ated ID O  enzym atic activity for each tim e point 
by calculating the kynurenine:tryptophan ratio x 103 (m m ol/ 
mol). W e calculated the quotient of tryptophan:C A A  x 103 to 
estim ate the tryptophan availability to the brain.
Results
During the 24 w eeks of treatm ent, 4 patients had  to d iscon­
tinue the treatm ent early because of som atic side effects. This 
m eant that 97 patients com pleted the 24 w eeks of the treat­
m ent; their data w ere included in the analysis (Table 1).
Depressive symptoms and diagnosis o f MDD
Total M A D RS score w as significantly increased com pared to 
baseline at all tim e points in the treatm ent group. A s w ell, 
43 patients (44%) fulfilled the criteria for M D D  at least once 
during the 24 w eeks of treatm ent (Table 2).
In the control group, the total M A D RS score (m ean ±  stan­
dard deviation [SD]) w as 8.0 ±  4.8 at baseline and 9.0 ±  5.2 
after 24 w eeks (not significant). W e observed no m ajor d if­
ferences in M A D RS scores at baseline betw een the treatm ent 
and control groups. W e did observe significant differences in 
M A D RS scores betw een the treatm ent and control groups at 
w eek 24 after the first exam ination (14.7 ±  7.4 for the treat­
m ent group v. 9.0 ±  5.2 for the control group; p <  0.001).
N one o f the participants in the control group fulfilled the 
criteria for M D D  at baseline or at 24 w eeks.
Kynurenine, tryptophan, anthranilic acid and kynurenic acid 
concentrations, IDO activity and tryptophan availability
In the treatm ent group ID O  activity (kynurenine:tryptophan 
ratio) w as significantly increased com pared to baseline at all 
tim e points. Tryptophan concentrations declined significantly 
during treatm ent, but kynurenine concentrations increased 
m arked ly com p ared  to baseline  for all tim e p oin ts except 
w eek 2 (Table 3 and Table 4).
Tryptophan availability (tryptophan:CA A  ratio) show ed a 
significant decrease (ß =  -0 .0 9 ; p =  0.01) only in w eek 12 of 
treatm ent. A nthranilic acid concentration  w as significantly 
increased  com pared  to baseline  for all tim e p oin ts except 
w eek 2. Kynurenic acid concentration show ed a statistically 
significant increase only in w eek 24 of treatm ent (ß =  0.20; p  =  
0.01) (Fig. 2).
In the control group at baseline, kynurenine levels (m ean ± 
SD) w ere 2.0 ±  0.75 p m o l/L , tryptophan levels w ere 36.1 ±
8.5 p m o l/L , anthranilic acid levels w ere 42.2 ±  28.6 n m o l/L , 
kynurenic acid levels w ere 30.2 ±  10.2 n m o l/L , ID O  activity 
w as 53.3 ±  19.5 and tryptophan availability w as 63.8 ±  12.5. 
W e observed no m ajor differences betw een the treatm ent and 
control groups at baseline.
Table 1: Baseline characteristics of study cohort and controls*
Characteristic
Patients treated with 
PEG-IFN-a-2a and oral RBV
(n = 97)
Controls awaiting treatment with 
PEG-IFN-a-2a and oral RBV 
(n =  40)
Overall cases, n 97 40
Age, yr 46.2 ± 9.9 44.2 ± 10.0
Sex, M/F 48/49 20/20
Weight, kg 77.8 ± 16.3 77.3 ± 14.6
Alanine aminotransferaze, IU/L 83 ± 52 79 ± 44
Serum HCV RNA x 106 lU/mL 2.0 ± 3.3 1.9 ± 3.0
History of MDD, n 9 3
History of substance abuse, n 31 10
Education, yr 13 ± 3 12 ± 3
HCV = hepatitis C virus; MDD = major depressive disorder; P EG -IFN -a2a = pegylated in terferon-a2a; RBV = ribavirin. 
*Unless otherw ise indicated, va lues are  mean ± standard deviation; all differences between groups were nonsignificant.
Table 2: MADRS score and participants with MDD in the treatm ent group (n = 97)
Week of treatment
Characteristic Baseline 2 4 8 12 24
Total MADRS score, mean ± SD 7.0 ± 4.8 11.3 ± 6.5 13.8 ± 7.5 14.7 ± 7.5 14.1 ± 7.3 14.7 ± 7.4
Patients with MDD, n (%) 0 18 (19) 29 (30) 39 (40) 36 (37) 40 (41)
MDD = major depressive disorder; MADRS = M ontgom ery-Ä sberg  Depression Rating Scale; SD = standard deviation.
Table 3: Kynurenine, tryptophan, kynurenic acid and anthranilic acid concentrations, IDO activity and tryptophan availability in the 
treatm ent group (n = 97)
Week of treatment*
Characteristic Baseline 2 4 8 12 24
Kynurenine, pmol/L 2.04 ± 0.66 2.11 ± 0.57 2.13 ± 0.69 2.22 ± 0.64 2.20 ± 0.61 2.41 ± 0.60
Tryptophan, pmol/L 35.1 ± 8.6 34.2 ± 7.1 33.7 ± 6.0 33.1 ± 8.2 32.3 ± 7.8 32.5 ± 7.1
Kynurenic acid, nmol/L 27.6 ± 9.3 26.2 ± 10.5 27.5 ± 12.1 30.5 ± 17.5 31.5 ± 16.5 34.0 ± 18.1
Anthranilic acid, nmol/L 44.6 ± 23.5 52.9 ± 24.4 59.0 ± 29.6 60.7 ± 26.5 49.9 ± 26.4 54.8 ± 18.8
IDO activity (KYN:TRP x 103) 57.1 ± 20.0 65.1 ± 20.1 67.1 ± 24.5 76.1 ± 23.8 82.0 ± 29.2 85.4 ± 26.2
Tryptophan availability (TRP:CAA x 103) 64.0 ± 13.0 64.2 ± 15.2 64.7 ± 11.9 64.5 ± 12.1 55.6 ± 12.2 59.3 ± 9.4
CAA = com peting am ino acid; IDO = indolam ine 2 ,3-dioxygenase; KYN 
*Values are mean ± standard deviation.
= kynurenine; TRP = tryptophan.
Table 4: Multilevel regression analyses indicating differences in kynurenine, tryptophan, kynurenic acid and anthranilic acid concentrations, 
IDO activity and tryptophan availability for each tim e point compared with baseline in the treatm ent group (n = 97)*
Week of treatment
2 4 8 12 24
Characteristic ß p value ß p value ß p value ß p value ß p value
MADRS 4.82 < 0.001 7.32 < 0.001 8.22 < 0.001 7.65 < 0.001 8.25 < 0.001
Kynurenine 0.07 NS 0.09 0.03 0.18 < 0.001 0.16 0.001 0.37 < 0.001
Tryptophan -0.09 0.007 -0.14 < 0.001 -0.20 < 0.001 -0.28 < 0.001 -0.26 < 0.001
Kynurenic acid -0.10 NS -0.01 NS 0.08 NS 0.10 NS 0.20 0.01
Anthranilic acid 0.14 NS 0.37 < 0.001 0.41 < 0.001 0.23 0.004 0.30 < 0.001
IDO activity (KYN:TRP x 103) 0.12 < 0.001 0.20 < 0.001 0.30 < 0.001 0.37 < 0.001 0.43 < 0.001
Tryptophan availability (TRP:CAA x 103) 0.03 NS 0.06 NS 0.04 NS -0.09 0.01 -0.06 NS
CAA = com peting am ino acid; IDO = indolam ine 2 ,3-dioxygenase; KYN = kynurenine; MADRS = M ontgom ery-Ä sberg  Depression Rating Scale; NS = not significant; TRP = tryptophan. 
*ß indicates the regression coefficient.
The second  assessm en t o f the con tro l group  took p lace  
24 w eeks after the first assessm ent. A t this point, kynurenine 
levels (m ean ±  SD) w ere 2.04 ±  0.70 p m o l/L , tryptophan lev­
els w ere 35.2 ±  7.5 p m o l/L , kynurenic acid levels w ere 31.3 ± 
12.2 n m o l/L , anthranilic acid  levels w ere 47.0 ±  30.2 n m o l/L , 
ID O  activity w as 59.1 ±  20.2 and tryptophan availability w as
62.5 ±  12.1. W e d etected  no m ajor d ifferences betw een the 
first and second assessm ents in the control group.
Laboratory assessment findings and their relationship with 
MADRS score and diagnosis o f MDD
K ynurenine, tryptophan and anthranilic acid concentrations, 
ID O  activity and tryptophan availability  w ere significantly 
associated  over tim e w ith  total M A D R S score (Table 5). A 
logistic regression m odel revealed the follow ing (Table 6). At
w eek 12 of treatm ent, participants w ith  changes in trypto­
phan availability  that w ere greater than the m edian had  a 
higher risk o f a diagnosis of M D D  (OR 2.92) than participants 
w ith changes that w ere low er than the m edian. A t w eek 24 of 
treatm ent, participants w ith  changes in anthranilic acid con­
centrations that w ere greater than the m edian had  a higher 
risk of a diagnosis of M D D  (OR 3.59) than participants w ith 
changes low er than the m edian.
Discussion
O ur m ain  find ing is con nected  w ith  the p ossib le  ro le o f an- 
thran ilic  acid  in the p ath o g en esis  o f d ep ression . W e found 
that an th ran ilic  acid  con cen tratio n s w ere sig n ificantly  in ­
creased  d uring  treatm en t w ith  P E G -IF N -a2a  and ribavirin ; 
th ey  w ere  s ig n ific a n tly  a sso c ia te d  o v er tim e  w ith  to ta l
Fig. 2: Changes in MADRS score, IDO activity (KYN:TRP), kynurenine, tryptophan and anthranilic acid concentrations, and tryptophan availability 
to the brain (TRP:CAA) during 24 weeks of treatment with PEG-IFN-a2a and oral ribavirin. Error bars indicate standard deviation. *p < 0.05; 
**p < 0.01; ***p < 0.001. Week 0 = baseline. AA = anthranilic acid; CAA = competing amino acid; IDO = indolamine 2,3-dioxygenase; KYN = kyn­
urenine; MADRS = Montgomery-Äsberg Depression Rating Scale; PEG-IFN-a2a = pegylated interferon-a2a; RBV = ribavirin; TRP = tryptophan.
Table 5: Relationship of kynurenine, tryptophan, kynurenic acid and 
anthranilic acid concentrations, IDO activity and TRP availability  
with MADRS score in the treatment group (n = 97)
Characteristic
MADRS* 
ß (95% CI) p value
Kynurenine 0.37 (0.12 to 0.62) 0.004
Tryptophan -1.01 (-1.31 to -0.72) < 0.001
Kynurenic acid -0.12 (-0.19 to 0.04) NS
Anthranilic acid 0.28 (0.04 to 0.47) 0.006
IDO activity (KYN:TRP x 103) 0.08 (0.02 to 0.12) 0.004
Tryptophan availability 
(TRP:CAA x 103)
-0.50 (-0.19 to -0.81) 0.001
CAA = com peting am ino acid; CI = confidence interval; IDO = indolamine 
2,3-dioxygenase; KYN = kynurenine; M ADRS = M ontgom ery-Ä sberg  Depression 
Rating Scale; NS = not significant; TRP = tryptophan.
*Linear model fo r logarythm ic values.
M A D R S score ; and  a t w eek  24 o f treatm en t, p artic ip an ts  
w ith  in c re a se d  a n th ra n ilic  ac id  c o n ce n tra tio n s  (g rea te r  
than  the m edian) had  a h igh er risk  o f a d iagnosis o f M D D  
(O R 3.59).
Increased  anth ran ilic  acid  con centrations have b een  re­
ported in schizophrenia, rheum atoid arthritis and type 1 dia­
b etes.31-33 To the b est o f our know ledge, the p resent study 
provides the first d irect evidence of a role for anthranilic acid 
in the pathogenesis of inflam m ation-induced M DD.
A n th ran ilic  acid  is one o f the  p ro d u cts  o f k y n u ren in e  
m etabolism , w hich converts kynurenine to anthranilic acid, 
kynurenic acid and 3-hydroxykynurenine. The conversion of 
kynurenine to anthranilic acid occurs under the influence of 
the kynureninase enzym e. Kynureninase is an enzym e pres­
ent m ostly in liver, kidney and spleen cells. Its activity in the 
brain am ounts to only 1% of its activity in the liver.34 Because
Table 6: Logistic regression model adapted for a diagnosis of MDD at each tim e point*
Diagnosis of MDD
Characteristic 2 4 8 12 24
A Kynurenine p > 0.1 p > 0.1 p > 0.1 p > 0.1 p > 0.1
A Tryptophan p > 0.1 p > 0.1 p > 0.1 p > 0.1 p > 0.1
A Kynurenic acid p > 0.1 p > 0.1 p > 0.1 p > 0.1 p > 0.1
A Anthranilic acid p > 0.1 p > 0.1 p > 0.1 p > 0.1 OR (95% CI) = 
3.59 (1.18 to 10.93) 
p = 0.024
A IDO activity (KYN:TRP x 103) p > 0.1 p > 0.1 p > 0.1 p > 0.1 p > 0.1
A Tryptophan availability 
(TRP:CAA x 103)
p > 0.1 p > 0.1 p > 0.1 OR (95% CI) = 
2.92 (1.01 to 8.42) 
p = 0.032
p > 0.1
CAA = com peting am ino acid; CI = confidence interval; IDO = indolam ine 2,3-dioxygenase; KYN = kynurenine; O R = odds ratio; TRP = 
tryptophan.
*This model takes into account the  changes (A) in kynurenine, tryptophan, kynurenic acid and anthranilic acid concentrations, IDO activity 
(K Y N :TR P ) and TRP availab ility  (TR P:C A A ) between a given point and the  baseline m easurem ent in treatm ent group. 
fG re a te r than the  median v. less than the  median.
of this, anthranilic acid  synthesis takes p lace m ostly in the 
p erip hery , entering the brain  by  passive d iffu sion .35,36 The 
n e x t  s ta g e  in  th e  k y n u re n in e  p a th w a y  is  b u ild u p  of 
3-hydroxyanthranilic acid (3HAA), w hich can be synthesized 
from both anthranilic acid and 3-hydroxykynurenine. Conver­
sion of 3-hydroxykynurenine into 3H AA also occurs under the 
influence of kynureninase enzym atic activity (i.e., the sam e 
enzym e that converts kynurenine into anthranilic acid). The 
enzym e's propinquity to 3-hydroxykynurenine (Km 25 gM) is 
10 times greater than to kynurenine (Km 250 gM),37 meaning 
that kynurenine m etabolism  through 3-hydroxykynurenine is 
the m ain source of 3H AA  in peripheral tissue (Fig. 1).
Because 3H A A  does n o t cross the b lo o d -b ra in  barrier,36 
n on sp ecific  h y d roxy lation  o f an th ran ilic  acid  rem ains the 
m ajor source of 3H A A  in the brain.38 Thus in the brain, per­
ipheral anthranilic acid is the preferred precursor for 3H AA  
production, w hereas in peripheral tissue, 3H A A  is produced 
from  3-hyd roxykynu ren ine. T his ties in w ith  data from  a 
s tu d y  b y  G io rg in i and  co lle a g u e s ,39 w h ich  sh o w ed  th a t 
genom ic depletion of kynurenine 3-m onooxygenase (KM O), 
con v ertin g  k y n u ren in e to 3-h y d roxyk yn u ren in e , red uced  
brain quinolinic acid levels by  only about 20% , and anthra- 
nilic acid levels w ere m arkedly increased.
W e know  th at 3H A A , an th ran ilic  acid  and  3-h y d roxy- 
kynurenine can inhibit the activity of com plexes of the respi­
ra to ry  ch a in ,40 w h ich  is co n n ected  w ith  im p a irm en ts  in 
m ito c h o n d r ia l  f u n c t io n in g .20 T h e re  is  e v id e n c e  th a t  
m ito ch o n d ria-m ed iated  m echanism s are related  to depres­
sive sym ptom s.41,42 A correlation has been found betw een cir­
culating m itochondrial DN A and inflam m ation.43
M ackay and colleagues44 found strong positive correlations 
betw een 3H A A  and scores on the M A D RS, H am ilton Rating 
Scale for Depression and Beck Depression Inventory (higher 
con centrations o f 3H A A  w ere associated  w ith  greater d e­
grees of depression at 6 w eeks in patients w ith  depression 
treated w ith fluoxetine).
In their stud y in m ice in fected  w ith  Plasmodium berghei 
A N KA , Clark and colleagues45 found that adm inistration of 
R o -6 1 -8 0 4 8  (a h igh -affin ity  inh ib itor o f K M O  synthesized
by F. H offm ann-La Roche Ltd.) generated a 40-fold increase 
in brain anthranilic acid in controls and a m ore than 200-fold 
increase in infected anim als. In this case, anthranilic acid ap­
p eared  to p lay  a protective role, although the theoretically 
h igh  an th ran ilic  acid  levels shou ld  h av e  cau sed  a rise in 
3H A A  in the brain, and, as a result, a rise in quinolinic acid.
Tashiro and colleagues46 investigated the role of K M O  in 
em otional and cognitive function using K M O  knockout m ice 
com pared  to w ild -typ e m ice. T heir resu lts suggested  that 
K M O  knockout m ice m ay be a novel anim al m odel for M DD. 
Serum  con cen tratio n s o f k y nu ren ine, kynu ren ic  acid  and 
anthranilic acid in the K M O  knockout m ice revealed dram at­
ically increased levels of kynurenine (44 737%  that o f w ild ­
type m ice), kynurenic acid (9000%  that o f w ild -typ e m ice) 
and anthranilic acid  (1470%  that of w ild-type m ice), as w ell 
as a decrease in 3H A A  (88%  that o f w ild -type m ice) and a 
lack  o f 3 -h y d ro x y k y n u ren in e  in  th e  seru m . T h is fin d in g  
seem s to be consistent w ith  predictions for the kynurenine 
p athw ay m odel (Fig. 1), given that in the case o f the KM O  
en z y m e  b lo ck a d e , k y n u re n in e  m e ta b o lism  fo llo w s  th e 
anthranilic acid and kynurenic acid production pathw ay.
W e are gradually uncovering m ore and m ore of the data 
requ ired  to answ er the qu estion  o f how  p erip h eral blood  
changes in ID O  catabolites m anifest in the brain. Raison and 
colleagues22 found that increased  kynurenine in peripheral 
blood w as correlated w ith increased kynurenine, quinolinic 
acid and kynurenic acid in cerebrospinal fluid. Kita and col- 
leagues47 show ed that after system ic im m une activation, kyn- 
urenine in the b rain  w as d erived  exclu siv ely  from  b lood , 
transported to the brain  by  large am ino acid transporters,36 
and brain quinolinic acid w as derived from  blood kynuren- 
ine (52% ), b lo o d  q u in o lin ic  acid  (40% ) and  b lo od  3H A A  
or 3 -h y d rox y k y n u ren in e  (8% ). T h u s, b lo o d  k y n u ren in e  is 
the m ain  so u rce  o f cen tra l n e rv o u s  sy stem  k y n u ren in e , 
3-hydroxykynurenine and quinolinic acid. A ccording to our 
findings, anthranilic acid concentrations w ere associated w ith 
depressive sym ptom s, and at w eek 24 of treatm ent, increased 
anth ran ilic  acid  con cen tratio n s (greater than  the m edian) 
w ere associated w ith M D D  (OR 3.59). Together w ith the fact
that anthranilic acid  can enter the brain by passive diffusions 
in significant quantities,37 anthranilic acid m ight be regarded 
as a second  (after kynurenine) im portan t accessib le "w in ­
d o w " into the central nervous system , w ith  resp ect to the 
activation of ID O  pathw ays.
So far, th e  b io lo g ic  im p o rta n ce  o f a n th ra n ilic  ac id  re ­
m ains un know n . O rig in a lly , it w as b e liev ed  to hav e b een  
a su b stra te  fo r 3H A A  p ro d u ction , and , con seq u en tly , for 
q u in o lin ic  ac id . H o w e v e r, in cre a se s  in  a n th ra n ilic  acid  
con cen tra tio n  ap p ear to h av e  a p ro tec tiv e  fu n ctio n  and  do 
n o t lea d  to a r ise  in  q u in o lin ic  a c id  c o n c e n tra tio n s ,40,46 
w h ich  m igh t b e  con n ected  to the  fact that an th ran ilic  acid  
is  a c o m p e tit iv e  in h ib ito r  o f  3 H A A  d io x y g e n a s e  an d  
m igh t th erefo re  red u ce th e con v ersio n  o f 3H A A  to q u in o ­
lin ic acid  and  p ico lin ic  ac id .48 T hu s, en d o gen o u s levels of 
a n th ran ilic  acid  lim it the  co n v ersio n  o f 3H A A  to q u in o ­
lin ic acid . A n th ran ilic  acid  m igh t also  p rev en t try p top h an  
d ep letio n  by  in h ib itin g  sod iu m  tra n sp o rters .49 H ow ever, 
w e s till kn ow  little  ab o u t the  ro le  o f an th ra n ilic  acid  in 
the brain .
It is h yp othesized  that the ratio o f 3H A A  to anthranilic 
acid is a m arker o f the assessm ent of inflam m ation and its 
progression,50 w hich could act as a com pensatory m echanism  
for the reduction of cell toxicity. A ccording to D arlington and 
colleagues,50 a decreased ratio of 3H A A  to anthranilic acid is 
responsible for a reduction in oxidative stress; it is also the 
antagonist of quinolinic acid and has a "clean u p " effect after 
brain injury or stroke.
T reatm en t w ith  P E G -IF N -a2a  and oral ribav irin  signifi­
cantly  increased  concentrations o f kynu renine and anthra- 
n ilic  ac id , an d  d ecre a se d  c o n ce n tra tio n s  o f try p to p h a n , 
lik e ly  d u e  to  th e  in d u c tio n  o f ID O  a c tiv ity , w h ich  w e 
observed  at all tim e points. D espite a decrease in total tryp­
tophan concentrations, tryptophan availability  to the brain 
w as stable up to 8 w eeks of treatm ent. M aintenance o f tryp­
tophan availability  to the brain  —  expressed  as the ratio of 
tryptophan to C A A s —  w as possib le thanks to a decrease in 
CA A  levels in the serum . Im m unotherapy w ith  in terferon-a  
a c tiv a te s  th e  in fla m m a to ry  re sp o n se  sy ste m , w h ich  in ­
creases the use of am ino acids by  leukocytes and the liver. 
A m ino acid  oxid ation  and  a h igher uptake by  the liver of 
branched -chain  am ino acids (valine, leucine and isoleucine) 
are activated.2 The branched -chain  am ino acids, along w ith 
p hen yla lan in e and  tyrosine, com p ete w ith  tryp top han  for 
tran sp o rt across th e b lo o d -b ra in  b arrier. The d ecrease  in 
CA A  levels in the serum  during in terfero n -a  im m unother­
apy has been  rep orted  by  o ther research ers.2,5,6 In light of 
th is, the  second  im p o rtan t find ing  o f our stu d y w as that 
after 12 w eeks o f treatm ent w ith  P E G -IFN -a2a and ribavi­
rin, the hom eostatic m echanism  o f decreasing CA A  levels at 
a ra te  p ro p o rtio n a te  to th a t o f th e  try p to p h a n  d ecrea se  
broke d ow n, resu lting in low er tryp top han  availab ility  to 
the b ra in  (ex p ressed  as th e  try p to p h a n :C A A  ra tio ). W e 
found that over tim e, the ratio of tryptophan to C A A s w as 
s ig n ifica n tly  a sso c ia te d  w ith  to ta l M A D R S sco re . T h ese 
findings corroborate the report of C apuron and  colleagues5 
that the d evelopm ent of dep ressive sym ptom s during in ter­
feron therapy is m ediated  by reduced  tryptophan availabil­
ity to the brain . A s w ell, from  a logistic  reg ressio n  m od el, 
our re su lts  rev ea led  th a t a t w eek  12 o f trea tm en t, p a rtic i­
p a n ts  w ith  decreased  tryptophan availability  (greater than 
the m edian) w ere at h igher risk (O R 2.92) of a d iagnosis of 
M D D . This result verged  on statistical significance because 
the O R C Is w ere very w ide and the low er bound  w as very 
close to 1 (1.02). H ow ever, in light o f the above find ings it 
also appeared  to hav e clin ical significance. O ur resu lts con­
firm ed the potential role of tryp top han d ep letion  in M D D . 
In a study o f 58 p atien ts w ith  M D D  and 189 controls, M yint 
and  c o lle a g u e s51 fo u n d  th a t th e m ean  try p to p h a n  in d ex  
(tryp top han:C A A ) in d ep ressed  p atien ts w as significantly  
lo w er th an  in  co n tro ls  (p =  0 .045). H o w ev er, g iv en  that 
m ean kynurenic acid  concentrations w ere low er in patients 
w ith  d ep ression  (p =  0.003), the auth ors con clud ed  that a 
red u ction  in n eu ro p ro tectiv e  m arkers p lays an im p ortan t 
role in the pathophysiology of M DD.
O u r fin d in g s also  em p h asized  an in terestin g  asp ect of 
the p ath og en esis o f d ep ression  related  to ID O  activation . 
A cco rd in g  to  R a iso n  an d  c o lle a g u e s ,22 im m u n o th e ra p y  
w ith  in terfero n -a  sign ificantly  d ecreased  tryp top han  con ­
c en tra tio n  in  th e  b lo o d  b u t d id  n o t ch a n g e  try p to p h a n  
con cen tratio n s in  cereb ro sp in al fluid. T hu s, a lth o u g h  the 
m echanism  of p erip heral ID O  activation  causes decreased  
tryp top han concentrations in the b lood , it does n o t lead to 
d ecreased  tryp top han availability  to the brain , b ecau se the 
levels of C A A s in the serum  d ecrease sim ultaneously . In ­
dep endent o f the ID O  activation  m echanism , d isturbances 
in the com p ensational m echanism  for CA A  d ecrease in the 
p e r ip h e r a l  b lo o d  a re  n e c e s s a r y  fo r  th e  d e c r e a s e  in  
tryptophan:C A A  ratio.
Data from  our study argue in favour of D antzer's hypoth­
esis: " It  is possible that depression represents a m aladaptive 
v ersio n  o f cy to k in e-in d u ced  sickn ess, w h ich  cou ld  occur 
w hen activation  of the innate im m une response is exacer­
bated in intensity a n d /o r  d uration ."10
W e show ed that the duration of inflam m ation during treat­
m en t for hep atitis  C w ith  P E G -IF N -a2a  and  ribav irin  is a 
very im portant factor. D uring different tim e periods, differ­
ent m echanism s acquire particular significance. In w eek 12 
of treatm ent, a "depletion m echanism " in the form  o f trypto­
p han  av ailab ility  to the brain  w as crucial for d iagnosis of 
M D D , w h ereas in w eek  24 o f trea tm en t it w as increased  
anth ranilic  acid  con centrations that had  an im p act on the 
incidence of M DD.
W e should rem em ber that M D D  is n o t a unified disease 
b ut a heterogen eou s syndrom e. A ccord ing to Rantala and 
colleagues,52 depression induced by infection is 1 of 12 d is­
crete depression subtypes. The others are induced by  long­
term  stress, loneliness, traum atic experience, h ierarchy con­
flict, grief, rom antic rejection, postpartum  events, the seasons, 
chem icals, som atic d iseases and starvation. A n experim ental 
interferon-a prospective m odel of M D D  could be instrum en­
tal in providing causal evidence for an association betw een 
inflam m ation and depression. Dooley and colleagues14 con­
clude that in flam m ation  likely p lays a role in exaggerated  
reactivity to negative inform ation, altered rew ard reactivity 
and som atic sym ptom s.
Limitations
Lim itations of this naturalistic study stem m ed from  its open- 
label design. However, the sm all num ber of participants pre­
clu ded  us from  con d u cting  fu rther subgroup  analyses. It 
should be noted that each patient w as evaluated in detail at 
6 tim e points over 24 w eeks. As well, given the lack of concomi­
tant biological measures such as cerebrospinal fluid concentra­
tions o f kynurenine, tryptophan, anthranilic acid and kyn- 
urenic acid, our findings should be approached w ith caution.
Conclusion
The m ain findings o f the current w ork are connected w ith the 
role of anthranilic acid and decreased tryptophan availability 
to the brain in the pathogenesis of inflam m ation-induced de­
pression during treatm ent for hepatitis C w ith PEG -IFN -a2a 
and ribavirin. O ur results reveal that each of these m echan­
ism s acquires clinical im portance in the incidence of M D D  at 
a different tim e point from  the beginning of the treatm ent.
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